mdm2 gene mediates the expression of mdr1 gene and P-glycoprotein in a human glioblastoma cell line

British Journal of Cancer

Volumn 74, Issue 8, 1996, Pages 1263-1268

  Kondo, S ^a   Kondo, Y ^b   Hara, H ^c   Kaakaji, R ^a   Peterson, J W ^b   Morimura, T ^c   Takeuchi, J ^c   Barnett, G H ^a  

^a Brain Tumor Institute   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UTANO NATIONAL HOSPITAL   (Japan)

Author keywords

Chemotherapy; Glioma; mdm2; mdr1; P glycoprotein

Indexed keywords

ETOPOSIDE; GLYCOPROTEIN P;

ARTICLE; CANCER CHEMOTHERAPY; CELL DEATH; GENE; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

EID: 0029823094     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.527     Document Type: Article

References (42)

1. ABRAHAM EH, PRAT AG, GERWECK L, SENEVERATNE T, ARCECI RJ, KRAMER R, GUIDOTTI G AND CANTIELLO HF. (1993). The multidrug resistance (mdr1) gene product functions as an ATP channel. Proc. Natl Acad. Sci. USA, 90, 312 - 316.
2. BARAK Y, JUVEN T, HAFFNER R AND OREN M. (1993). mdm2 expression is induced by wild-type p53 activity. EMBO J., 12, 461 - 468.
3. CAHILLY-SNYDER L, YANG-FENG T, FRANCKE U AND GEORGE DL. (1987). Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somatic Cell Mol. Genet., 13, 235 - 244.
4. CHABNER BA AND WILSON W. (1991). Reversal of multidrug resistance (editorial). J. Clin. Oncol., 9, 4 - 6.
5. CHAN HSL, HADDAD G, THORNER PS, DEBOER G, LIN YP, ONDRUSEK N, YEGER H AND LING V. (1991). P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N. Engl. J. Med., 325, 1608 - 1614.
6. CHIN K-V, UEDA K, PASTAN I AND GOTTESMAN MM. (1992). Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science, 255, 459 - 462.
7. CROOK T, WREDE D, TIDY JA, MASON WP, EVANS DJ AND VOUSDEN KH. (1992). Clonal p53 mutation in primary cervical cancer: assocation with human-papillomavirus-negative tumours. Lancet, 339, 1070 - 1073.
8. CROOP JM, RAYMOND M, WABER D, DEVAULT A, ARCECI RJ, GROSP P AND HOUSMAN DE. (1989). The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol. Cell Biol., 9, 1346 - 1350.
9. FAKHARZADEH SS, TRUSKO SP AND GEORGE DL. (1991). Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumour cell line. EMBO J., 10, 1565-1569.
10. FINLAY CA. (1993). The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol. Cell Biol., 13, 301 - 306.
11. FOJO AT, UEDA K, SLAMON DJ, POPLACK DG, GOTTESMAN MM AND PASTAN I. (1987). Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl Acad. Sci. USA, 84, 265 - 269.
12. GAVRIELI Y, SHERMAN Y AND BEN-SASSON SA. (1992). Identification of programmed cell death in situ via specific labelling of nuclear DNA fragmentation. J. Cell Biol., 119, 493 - 501.
13. GINSBERG D, OREN M, YANIV M AND PIETTE J. (1990). Protein-binding elements in the promoter region of the mouse p53 gene. Oncogene, 5, 1285 - 1290.
14. GOLDSTEIN LJ AND OZOLS RF. (1991). Blocking P-glycoprotein action. Contemporary Oncol. May/June, 38 - 47.
15. GOLDSTEIN LJ, GALSKI H, FOJO A, WILLINGHAM M, LAI S-L, GAZDAR A, PIRKER R, GREEN A, CRIST W, BRODEUR GM, LIEBER M, COSSMAN J, GOTTESMAN MM AND PASTAN I. (1989). Expression of multidrug resistance gene in human cancers. J. Natl Cancer Inst., 81, 116 - 124.
16. GROS P, BEN-NERIAH Y, CROOP JM AND HOUSMAN DE. (1986). Isolation and expression of a complementary DNA that confers multidrug resistance. Nature, 323, 728 - 731.
17. HARRIS CC AND HOLLSTEIN M. (1993). Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med., 329, 1318 - 1327.
18. HINDS PW, FINLAY CA, QUARTIN RS, BAKER SJ, FEARON ER, VOGELSTEIN B AND LEVIN AJ. (1990). Mutant p53 cDNAs from human colorectal carcinomas can cooperate with ras in transformation of primary rat cells: a comparison of the 'hot spot' mutant phenotype. Cell Growth Different., 1, 571 - 580.
19. HOLLSTEIN M, SIDRANSKY D, VOGELSTEIN B AND HARRIS CC. (1991). p53 mutations in human cancers. Science, 253, 49 - 53.
20. JULIANO RL AND LING V. (1976). A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta, 455, 152 - 162.
21. KONDO S, YIN D, MORIMURA T, ODA Y, KIKUCHI H AND TAKEUCHI J. (1994). Transfection with a bcl-2 expression vector protects transplanted bone marrow from chemotherapy-induced myelosuppression. Cancer Res., 54, 2928 - 2933.
22. KONDO S, BARNETT GH, HARA H, MORIMURA T AND TAKEUCHI J. (1995). MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene. 10, 2001 - 2006.
23. LEVINE AJ, MOMAND J AND FINLAY CA. (1991). The p53 tumour suppressor gene. Nature, 351, 453 - 456.
24. LOWE SW, RULEY HE, JACKS T AND HOUSMAN DE. (1993). p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74, 957 - 967.
25. MA DD, DAVEY RA, HARMAN DH, ISBISTER JP, SCURR RD, MACKERTICH SM, DOWDEN G AND BELL DR. (1987). Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukemia. Lancet, 1, 135 - 137.
26. MOMAND J, ZAMBETTI GP, OLSON DC, GEORGE D AND LEVINE AJ. (1992). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69, 1237-1245.
27. OLINER JD, KINZLER KW, MELTZER PS, GEORGE DL AND VOGELSTEIN B. (1992). Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature, 358, 80-83.
28. OLINER JD PIETENPOL JA, THIAGALINGAM S, GYURIS J, KINZLER KW AND VOGELSTEIN B. (1993). Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature, 362, 857-860.
29. OLSON DC, MARECHAL V, MOMAND J, CHEN J, ROMOCKI C AND LEVINE AJ. (1993). Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene, 8, 2353-2360.
30. ONISHI Y, AZUMA Y, SATO Y, MIZUNO Y, TADAKUMA T AND KIZAKI H. (1993). Topoisomerase inhibitors induce apoptosis in thymocytes. Biochim. Biophys. Acta, 1175, 147 - 154.
31. REIFENBERGER G, LIU L, ICHIMURA K, SCHMIDT EE AND COLLINS VP. (1993). Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res., 53, 2736-2739.
32. RONINSON IB, ABELSON HT, HOUSMAN DE, HOWELL N AND VARSHAVSKY A. (1984). Amplification of specific DNA sequences correlates with multidrug-resistance in Chinese hamster cells. Nature, 309, 626-628.
33. SAFA AR, GLOVER CJ, MEYERS MB, BIEDLER JL AND FELSTAD RL. (1986). Vinblastine photoaffinity labelling of a high molecular weight surface membrane glycoprotein specific for multidrug-resistant cells. J. Biol. Chem., 261, 6137-6140.
34. SARKADI B, PRICE EM, BOUCHER RC, GERMANN V AND SCABOROUGH GA. (1992). Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J. Biol. Chem., 267, 4854-4858.
35. SCHEFFNER M, WERNESS BA, HUIBREGSTE JM, LEVINE AJ AND HOWLEY PM. (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell, 63, 1129-1136.
36. SCHURR E, RAYMOND M, BELL J AND GROS P. (1989). Characterization of the multidrug resistance protein expressed in cell clones stably transfected with the mouse mdr1 cDNA. Cancer Res., 49, 2729-2734.
37. SIDRANSKY D, MIKKELSEN T, SCHWECHHEIMER K, ROSENBLUM ML, CAVANEE W AND VOGELSTEIN B. (1992). Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature, 355, 846-847.
38. THIEBAUT T, TSURURO T, HAMADA H, GOTTESMAN MM, PASTAN I AND WILLINGHAM MC. (1987). Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl Acad. Sci. USA, 84, 7735-7738.
39. UEDA K, CARDARELLI C, GOTTESMAN MM AND PASTAN I. (1987). Expression of a full-length cDNA for the human 'MDR1' gene confers resistance to colchicine, doxorubicine, and vinblastine. Proc. Natl Acad. Sci. USA, 84, 3004-3008.
40. VOGHLSTEIN B AND KINZLER KW. (1992). p53 function and dysfunction. Cell, 70, 523-526.
41. YIN D, KONDO S, TAKEUCHI J AND MORIMURA T. (1994). Induction of apoptosis in murine ACTH-secreting pituitary adenoma cells by bromocriptine. FEBS Lett., 339, 73-75.
42. ZASTAWNY RL, SALVINO R, CHEN J, BENCHIMOL S AND LING V. (1993). The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Oncogene, 8, 1529-1535.